To confirm our hypothesis that the inflammation seen in fibrotic NASH patients might lead the way to cancer, we investigated the level of the two calgranulins, S100A8 and S100A9, in the serum of patients affected by NASH. This evidence concerns the gene S100A9 and metabolic dysfunction-associated steatohepatitis.